Skip to main content
. Author manuscript; available in PMC: 2020 Aug 5.
Published in final edited form as: Circulation. 2018 Nov 10;139(25):e1082–e1143. doi: 10.1161/CIR.0000000000000625

Figure 1. Secondary prevention in patients with clinical ASCVD.

Figure 1.

Colors correspond to Class of Recommendation in Table 2. Clinical ASCVD consists of acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Very high-risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions (Table 4). ACS indicates acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; MI, myocardial infarction; and PCSK9i, PCSK9 inhibitor.